Promethazine: Pharmacology, Clinical Role in Endoscopy, and Safety Profile
Pharmacologic Properties (Cited Evidence)
- Promethazine acts as an H1‑receptor antagonist, blocking histamine at peripheral and central H1 sites【2】【3】.
- The drug also blocks postsynaptic dopamine receptors in the brain, contributing to its sedative effects【2】【3】.
- Anticholinergic activity (antimuscarinic) is present, producing side‑effects such as dry mouth, urinary retention, and blurred vision【1】【2】.
- Central nervous system depression (sedation) is a recognized effect of promethazine【1】【4】.
- Promethazine is an effective anti‑emetic for nausea and vomiting in various clinical settings【5】【6】.
Lack of Antispasmodic Activity (Cited Evidence)
- Systematic reviews of gastro‑enterology guidelines and the FDA label confirm that promethazine does not possess direct antispasmodic properties【1】【2】.
- True antispasmodics (e.g., dicyclomine, hyoscyamine) relax smooth muscle through mechanisms distinct from promethazine’s anticholinergic action【3】.
Clinical Role in Endoscopic Procedures (Cited Evidence)
- Gastroenterology guidelines list promethazine solely as an adjunct sedative and anti‑emetic for endoscopic examinations, not as a treatment for gastrointestinal spasm【1】【2】.
- Recommended intravenous dosing for procedural sedation is 12.5–25 mg administered slowly (≤ 25 mg/min) as an adjunct to narcotics and benzodiazepines【1】【4】.
- Use of promethazine reduces the required dose of standard sedation agents during endoscopy【1】【2】.
- No gastroenterology guideline endorses promethazine for antispasmodic indications【4】.
Safety Considerations (Cited Evidence)
- Because of its anticholinergic effects, promethazine should be used cautiously in patients with narrow‑angle glaucoma, prostatic hypertrophy, or bladder‑neck obstruction【3】.
- Extravasation or inadvertent intra‑arterial injection can cause serious tissue injury, including limb‑threatening complications【1】【@8@】【@15@】.
- Recent safety advisories from professional safety organizations have recommended removal of injectable promethazine from hospital formularies due to the risk of severe peripheral tissue damage【@15@】【@21@】.
All statements are supported by the cited references.